CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Suspension of heat killed (autoclaved) Mycobacterium wWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2343 Standard therapy of COVID-19 Wiki 0.58
drug1822 Placebo Wiki 0.07

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D009164 Mycobacterium Infections NIH 0.87
D016638 Critical Illness NIH 0.16

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 3 clinical trials

Clinical Trials


1 A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection

The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone in critically ill adult patients suffering from COVID-19 infection.

NCT04347174 COVID-19 Drug: Suspension of heat killed (autoclaved) Mycobacterium w Drug: Standard therapy of COVID-19
MeSH:Mycobacterium Infections Critical Illness

Primary Outcomes

Description: To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction

Measure: Sequential Organ Failure Assessment (SOFA) scores

Time: Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 3

Description: To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) scores which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction

Measure: Sequential Organ Failure Assessment (SOFA) scores

Time: Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 7

Description: To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) scores which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction

Measure: Sequential Organ Failure Assessment (SOFA) scores

Time: Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 14

Description: To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) scores which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction

Measure: Sequential Organ Failure Assessment (SOFA) scores

Time: Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 21

Description: To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) scores which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction

Measure: Sequential Organ Failure Assessment (SOFA) scores

Time: Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 28

Description: To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) scores which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction

Measure: Sequential Organ Failure Assessment (SOFA) scores

Time: Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day of transfer from ICU, if earlier than 28 days.

Description: To study the effect of Mw on recovery of organ function as assessed by Ordinal scale

Measure: 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Time: Change in Ordinal scale from baseline to day 3

Description: To study the effect of Mw on recovery of organ function as assessed by Ordinal scale

Measure: 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Time: Change in Ordinal scale from baseline to day 7

Description: To study the effect of Mw on recovery of organ function as assessed by Ordinal scale

Measure: 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Time: Change in Ordinal scale from baseline to day 14

Description: To study the effect of Mw on recovery of organ function as assessed by Ordinal scale

Measure: 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Time: Change in Ordinal scale from baseline to day 21

Description: To study the effect of Mw on recovery of organ function as assessed by Ordinal scale

Measure: 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Time: Change in Ordinal scale from baseline to day 28

Description: To study the effect of Mw on recovery of organ function as assessed by Ordinal scale

Measure: 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Time: Change in Ordinal scale from baseline to day of transfer from ICU, if earlier than 28 days.

Secondary Outcomes

Description: All-cause mortality

Measure: All-cause mortality

Time: Till day 28

Description: Any AE / SAE or event of clinical significance observed during the study.

Measure: Incidence of AE / SAE or event of clinical significance

Time: Till day 28

Description: Percent of subjects with SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample.

Measure: SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample

Time: At days 3, 7, 14, 21, and 28

Description: ICU length of stay

Measure: ICU length of stay

Time: Till day 28

Description: Duration of mechanical ventilation

Measure: Duration of mechanical ventilation

Time: Till day 28

Description: Duration of hospitalization

Measure: Duration of hospitalization

Time: Till day 28

Description: Percentage of subjects having clinical improvement defined as two-point improvement on a seven category ordinal scale.

Measure: Clinical improvement

Time: From base line at day 14 & Day 28

Description: Time (in days) from treatment initiation to death.

Measure: Time (in days) from treatment initiation to death

Time: Till day 28

2 A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.

This clinical trial is a randomized, blinded, two arms, placebo controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice to prevent COVID 19 in subjects at risk of getting infected with COVID 19.

NCT04353518 COVID-19 Drug: Suspension of heat killed (autoclaved) Mycobacterium w Other: Placebo
MeSH:Mycobacterium Infections

Primary Outcomes

Description: To compare proportion of subjects acquiring COVID-19 infection between two arms over the time till 8 weeks from administration of 1st dose

Measure: Number of subject acquiring COVID-19 infection

Time: From first dosing to week 1, week 2, week 4, week 8 or at any time during the study till 8 week post first dosing..

Secondary Outcomes

Description: Any AE / SAE observed during the study.

Measure: Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)

Time: Till 8 weeks

Description: Whether administration of Mw prevents development of Upper Respiratory Tract Infection (URTI) symptoms in close contacts of COVID-19 patients.

Measure: Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms

Time: From first dosing to week 1, week 2, week 4, week 8 or at any time during the study till 8 week post first dosing.

Description: Whether administration of Mw prevents development of severe COVID-19 infection.

Measure: Number of subject developing severe COVID-19 infection based on ordinal scale

Time: From first dosing to week 1, week 2, week 4, week 8 or at any time during the study till 8 week post first dosing

3 A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill.

This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for preventing the progression of COVID-19 disease and for reduction in transfer to ICU in COVID-19 infected patients admitted to the hospital.

NCT04358809 COVID-19 Drug: Suspension of heat killed (autoclaved) Mycobacterium w Other: Placebo
MeSH:Mycobacterium Infections Critical Illness

Primary Outcomes

Description: To compare the difference in proportion of patients with increased disease severity

Measure: Number of patients with increased disease severity

Time: From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing.

Secondary Outcomes

Description: To evaluate safety of Mw in COVID-19 patients admitted to hospital

Measure: Incidence of adverse events and serious adverse events (Safety)

Time: Till day 28

Description: To compare the proportion of patients discharged from hospital

Measure: Number of COVID-19 patients discharged from hospital

Time: From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing.

Description: To compare the proportion of patients transfer to ICU

Measure: Number of COVID-19 patients transfer to ICU

Time: From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing.

Description: To compare the proportion of patients with reduction in disease severity by 1 ordinal scale

Measure: Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale

Time: From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing.

Description: To compare the proportion of symptom free patients

Measure: Number of of symptom free patients

Time: From baseline to Day 3, Day 7, Day 14, Day 21, Day 28 or at any time during the study till 28 days post first dosing.


No related HPO nodes (Using clinical trials)